Trial Information

Summary: The Diabetes-Endocrinology Center of WNY under the direction of Dr. Paresh Dandona is currently conducting a study involving post-menopausal women with osteopenia.

The purpose of this study is to find out if the medication Celecoxib works in limiting further bone loss in postmenopausal women who are showing signs of bone loss (osteopenia).

Osteopenia is a condition where some bone loss has occurred, and if untreated, could continue and eventually result in osteoporosis and bone fractures.

This study is a 14-week study assessing bone resorption activity of the FDA approved medication Celecoxib (Celebrex) 400mg. This research project will consist of 5 visits to our clinic in which you will randomly be selected to receive one of the following: Celecoxib alone, Estrace (estrogen therapy) alone, Estrace in combination with Celecoxib or a placebo (pills with no medication). You will also receive Calcium 500mg plus vitamin D 200 IU as a supplement throughout the project. At each of these visits we will monitor your vital signs, perform laboratory tests including blood and urine sample collection and physical exams. In addition there will be 2 bone density assessments by a DEXA screen and a quality of life questionnaire to be filled out.

All study medications, laboratory tests, physical exams, and parking will be of no cost to you. You will also be reimbursed for your time and travel.

To qualify, you must be a post-menopausal woman age 60 or older and are not taking Celebrex, anti-inflammatory agents or pain medication for arthritic discomfort. If you feel you may qualify for this research study and are interested in participating, please feel free to contact one of our knowledgeable research associates at 716-887-4486 or 716-887-5107 for more information.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.